Wu, Chih-Hsun <br/><br/>
Risk stratification for lung adenocarcinoma on EGFR and TP53 mutation status, chemotherapy, and PD-L1 immunotherapy.  [electronic resource] 

 -  Cancer medicine  10 2019 
 - 5850-5861 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2045-7634 
<br/><br/><label>Standard No.: </label>10.1002/cam4.2492  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma of Lung--drug therapy<br/>Antineoplastic Agents--therapeutic use<br/>B7-H1 Antigen--antagonists & inhibitors<br/>ErbB Receptors--genetics<br/>Gene Expression Regulation, Neoplastic<br/>Humans<br/>Immunotherapy<br/>Lung Neoplasms--drug therapy<br/>Mutation<br/>Neoplasm Staging<br/>Prognosis<br/>Risk Assessment<br/>Survival Analysis<br/>Tumor Suppressor Protein p53--genetics